InMed files PCT patent application for INM-901 treating Alzheimer's and neurodegeneration

InMed Pharmaceuticals Inc.

PCT patent covers composition, method of use for INM-901 in neurodegenerative diseases including Alzheimer's.
Patent claims neuroprotection, neurite elongation, cognitive/memory improvement, and anti-inflammatory effects.
InMed now has 14 patent families; eight on drug composition/formulations, six on manufacturing technologies.
Company plans to present long-term in vivo data for INM-901 in coming weeks.
INM-901 is an oral small molecule with CB1/CB2 and PPAR activity, targeting multiple Alzheimer's pathways.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.